Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF – Get Rating) shares dropped 3.4% during mid-day trading on Thursday . The company traded as low as $1.66 and last traded at $1.73. Approximately 24,926 shares changed hands during trading, a decline of 70% from the average daily volume of 82,503 shares. The stock had previously closed at $1.79.
Analyst Ratings Changes
Several research firms have recently weighed in on CANF. StockNews.com upgraded Can-Fite BioPharma from a "sell" rating to a "hold" rating in a report on Saturday, April 1st. Dawson James cut Can-Fite BioPharma from a "buy" rating to a "neutral" rating in a research note on Tuesday, January 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $34.00 price target on shares of Can-Fite BioPharma in a research note on Monday, March 13th.
Get Can-Fite BioPharma alerts:Can-Fite BioPharma Price Performance
The firm has a 50 day moving average of $2.70 and a two-hundred day moving average of $1.97.
Institutional Investors Weigh In On Can-Fite BioPharma
A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Virtu Financial LLC acquired a new stake in shares of Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF – Get Rating) during the second quarter, according to its most recent filing with the SEC. The fund acquired 56,322 shares of the biotechnology company's stock, valued at approximately $52,000. Virtu Financial LLC owned 0.21% of Can-Fite BioPharma as of its most recent filing with the SEC. Institutional investors and hedge funds own 1.82% of the company's stock.
Can-Fite BioPharma Company Profile
(Get Rating)
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
Featured Stories
- Get a free copy of the StockNews.com research report on Can-Fite BioPharma (CANF)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation's Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.